# **Special Issue**

# New Development in Pharmacotherapy of Kidney Diseases

## Message from the Guest Editor

We are pleased to invite you to submit your research papers for a Special Issue of our journal, focusing on recent advances in pharmacotherapy for patients with kidney disease. This Special Issue aims to highlight the latest developments and innovations in the treatment of patients with both chronic and acute kidney disease, with an emphasis on cardiovascular and kidney protection, as well as the improvement of quality of life. Additionally, it will cover therapies that benefit bone health, endocrine function, electrolyte/mineral balance, gastrointestinal health, hematology, metabolism, neuromuscular function, and nutrition. We also welcome submissions on therapies that address specific symptoms and procedures related to kidney disease, such as uremic pruritus and the survival of dialysis access. We believe that your contributions will significantly enhance the understanding and management of kidney disease, ultimately improving patient outcomes and quality of life. We look forward to receiving your submissions and to the valuable insights your research will bring to this Special Issue.

## **Guest Editor**

Dr. Chihchao Yang

Division of Nephrology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan

## Deadline for manuscript submissions

25 November 2025



# **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/221122

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





## **Pharmaceutica**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

### Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

## **Author Benefits**

## Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

